Morning Call, May 23
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$0.42 0.01 | 1.75%
05/23/13 - 04:00 PM ET
797.75K / 3.37M
Vol / Avg. Vol:0.41 / 0.42
Open / Prev. Close:0.40 - 0.43
Today's Range:0.38 - 2.38
52 Wk Range:-66.04%
Performance YTD:TheStreet Rating:
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Portfolio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
Latest DCTH Headlines from TheStreet
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- Stock Futures Eye Rebound on ECB Stimulus, U.S. Data 05.02.13 | 08:05 am
- Aveo, Delcath FDA Panel Live Blog 05.02.13 | 07:05 am
- FDA Tells Delcath No Approval Without New Clinical Trial 04.30.13 | 10:04 am
- Prepping for Aveo, Delcath FDA Panels 04.29.13 | 02:04 pm
- Biotech's Next Big Thing: Aveo
04.25.13 | 09:04 am - Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm 03.15.13 | 06:03 am
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
Press Releases for DCTH
- Delcath To Present At JMP Securities Healthcare Conference On July 12 - PR Newswire 07.09.12 | 04:07 pm
- Delcath Announces First CHEMOSAT Procedures In Germany - PR Newswire 02.27.12 | 06:02 am
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
- Delcath Submits CE Mark Technical File For Hepatic ChemoSAT⢠Delivery System - PR Newswire 12.06.10 | 06:12 am
- Delcath Names Bernard R. Tyrrell As Senior Vice President For North American Sales And Marketing - PR Newswire 12.01.10 | 06:12 am
- Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010 - Business Wire 11.10.10 | 05:11 pm
Partner Headlines for DCTH
- The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems - Seeking Alpha 05.06.13 | 09:05 am
- Is Delcath The Post-Celsion Play On Liver Cancer? - Seeking Alpha 02.04.13 | 09:02 am
- Morning Market Losers - Benzinga 10.15.12 | 09:10 am
- Benzinga's Microcap Movers for Friday October 5, 2012 - Benzinga 10.06.12 | 06:10 pm
- Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst - Seeking Alpha 09.28.12 | 09:09 am
- Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO - GuruFocus 06.11.12 | 01:06 pm
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer - NASDAQ 05.25.12 | 04:05 pm
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
